Infusion market structurally sound despite COVID; better triage in the future
“There are structural changes in the market, primarily how people seek care. But more importantly, is how long is this COVID pandemic and preventive matters will stick with us. And how long it will take us to get herd immunity and people feel more comfortable with doing things differently. I think there’s huge adaptability that we’re seeing — hospitals have these separate wards. And we believe that there are some changes in how people consult with primary care physicians,” Baxter CEO Joe Alameida said in a Motley Fool analyst call transcript. “People who have cancer, unfortunately, need an infusion. They need infusion, they either needed to do an infusion center and they need to go home and have it done in a place that is safe. People who need surgery will need to have the surgery, no matter what. Otherwise, they go in and they’re sicker later. People who need to be admitted because they have issues, need to. So, I believe that the return of pre-COVID that will happen with changes in technology, that will allow for better triage.”